“We believe that pancreatic cancer patients whose tumors have a reduced expression of G alpha 13 might benefit from therapies targeting the mTOR signaling pathway,” said Mario A. Shields, ’12 PhD, research assistant professor of Medicine in the Division of Hematology and Oncology and lead author of the study. Read more . . .
Northwestern Medicine investigators have discovered that targeting the G alpha 13 protein in pancreatic tumors promotes tumor growth and progression, according to a study published in Cell Reports. They also showed that human and mice pancreatic tumors with reduced G alpha 13 exhibited increased mTOR signaling, and targeting the mTOR signaling pathway reduced tumor growth in the mice.